Revelation Biosciences Inc (REVB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.43M
Last updated: Nov 17, 2026 at 4:25 PM ET
Revelation Biosciences Inc (REVB) Statistics
Revelation Biosciences (REVB) has a market cap of $2.43M. It holds $9.12M more cash than debt, 375.84% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $2.43M |
|---|---|
| Latest price (Nov 17, 2026) | $3.90 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 84.51% over 52 weeks and trades 22.47% below its 50-day average.
| Beta (1Y) | 1.70 |
|---|---|
| 52-Week Change | -84.51% |
| 1-Month Change | +18.72% |
| 3-Month Change | -49.81% |
| 6-Month Change | -45.91% |
| 5-Year Change | -100.00% |
| Total Return (1Y) | -84.51% |
| Total Return (3Y CAGR) | -94.67% |
| Total Return (5Y CAGR) | -95.15% |
| Return vs SPY (1Y) | -95.36% |
| Max Drawdown (1Y) | -89.80% |
| Max Drawdown (3Y) | -99.99% |
| Sharpe Ratio (1Y) | -2.05 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $5.03 |
| 200-Day Average | $7.26 |
| 52-Week Range | $0.47 to $6.93 |
| RSI (14 Days) | 43.4 |
| Average Volume (20 Days) | 14.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.98x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.98x |
|---|---|
| Quick Ratio | 3.98x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -168.09% and return on assets is -121.32% over the last 12 months.
| Return on Equity (ROE) | -168.09% |
|---|---|
| Return on Assets (ROA) | -121.32% |
| Return on Capital Employed (ROCE) | -158.02% |
| ROIC (5Y Average) | -79.47% |
Scores
REVB has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$5.85K |
| Operating Income | -$12.71M |
| Pretax Income | -$12.16M |
| Net Income | -$12.16M |
| EBITDA | -$12.13M |
| EBIT | -$12.16M |
| Reported EPS (TTM) | -$11.15 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.16% of the $10.02M in total assets.
| Cash and Equivalents | $9.12M |
|---|---|
| Total Debt | $0 |
| Net Cash | $9.12M |
| Net Cash Per Share | $16.30 |
| Working Capital | $6.94M |
| Shareholder Equity | $7.23M |
| Book Value Per Share | $12.93 |
| Total Assets | $10.02M |
| Total Liabilities | $2.79M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$10.10M |
|---|---|
| FCF Per Share | -$17.94 |
| Depreciation and Amortization | $29.55K |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
REVB does not pay a dividend.
| Buyback Yield | 0.00% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-7 reverse split on Oct 20, 2026.
| Last Split Date | Oct 20, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:7 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About REVB
What is REVB's market cap?
Revelation Biosciences has a market cap of $2.43M.
How many shares of REVB are outstanding?
Revelation Biosciences has 559.60K shares outstanding.
Does REVB pay a dividend?
No. Revelation Biosciences does not pay a dividend.
How much debt does REVB have?
Revelation Biosciences has $0 of total debt and $9.12M of cash and equivalents, a net cash position of $9.12M.
REVB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors